Renal fibrosis is attenuated by targeted disruption of KCa3.1 potassium channels

Ivica Grgic1, Eva Kiss, Brajesh P Kaistha

  • 1Department of Internal Medicine and Nephrology, Philipps-University, 35033 Marburg, Germany.

Insights

Blocking the intermediate-conductance Ca(2+)-activated K(+) channel (K(Ca)3.1) inhibits renal fibroblast proliferation and reduces kidney fibrosis. Targeting K(Ca)3.1 offers a potential therapeutic strategy for fibrotic kidney disease.

Area of Science:

  • Nephrology
  • Cell Biology
  • Pharmacology

Background:

  • Interstitial fibroblast proliferation drives renal fibrosis and chronic kidney failure.
  • The intermediate-conductance Ca(2+)-activated K(+) channel (K(Ca)3.1) is implicated in mitogenesis and proliferative diseases.

Purpose of the Study:

  • To investigate the role of K(Ca)3.1 in renal fibroblast proliferation and the development of kidney fibrosis.
  • To determine if K(Ca)3.1 deficiency or blockade can suppress renal fibrosis.

Main Methods:

  • Assessed K(Ca)3.1 expression and function in murine renal fibroblasts under mitogenic stimulation.
  • Utilized unilateral ureteral obstruction (UUO) model in K(Ca)3.1 knockout and wild-type mice, and treated wild-type mice and rats with a K(Ca)3.1 blocker (TRAM-34).
  • Evaluated fibrotic markers, tubulointerstitial damage, collagen deposition, and alphaSMA expression in kidneys.

Main Results:

  • Mitogenic stimulation upregulated K(Ca)3.1 in renal fibroblasts via a MEK-dependent pathway.
  • Selective K(Ca)3.1 blockade inhibited fibroblast proliferation by inducing G(0)/G(1) arrest.
  • K(Ca)3.1 knockout mice exhibited reduced renal fibrosis markers and damage post-UUO.
  • Pharmacological inhibition of K(Ca)3.1 attenuated UUO-induced renal fibrosis in mice and rats.

Conclusions:

  • K(Ca)3.1 plays a crucial role in renal fibroblast proliferation and fibrogenesis.
  • K(Ca)3.1 represents a promising therapeutic target for treating fibrotic kidney diseases.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...